In a filing, Arbutus Biopharma Corp revealed its Director McElhaugh Michael J. acquired Company’s shares for reported $0.8 million on Apr 21 ’25. In the deal valued at $3.26 per share,246,886 shares were bought.
Then, McElhaugh Michael J. bought 53,114 shares, generating $170,098 in total proceeds.
Before that, Sofia Michael J. bought 250,000 shares. Arbutus Biopharma Corp shares valued at $875,000 were divested by the Officer at a price of $3.50 per share.
Jefferies upgraded its Arbutus Biopharma Corp [ABUS] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late February with a ‘”a Hold”‘ rating. H.C. Wainwright began covering ABUS with “Buy” recommendation on December 17, 2020.
Price Performance Review of ABUS
On Tuesday, Arbutus Biopharma Corp [NASDAQ:ABUS] saw its stock jump 2.56% to $3.21. Over the last five days, the stock has gained 0.63%. Arbutus Biopharma Corp shares have fallen nearly -1.83% since the year began. Nevertheless, the stocks have risen 11.07% over the past one year. While a 52-week high of $4.72 was reached on 05/02/25, a 52-week low of $2.70 was recorded on 04/09/25. SMA at 50 days reached $3.28, while 200 days put it at $3.56.
Levels Of Support And Resistance For ABUS Stock
The 24-hour chart illustrates a support level at 3.12, which if violated will result in even more drops to 3.02. On the upside, there is a resistance level at 3.27. A further resistance level may holdings at 3.32. The Relative Strength Index (RSI) on the 14-day chart is 47.23, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.15, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 65.61%. Stochastics %K at 25.48% indicates the stock is a holding.
